ESTRO 2024 - Abstract Book

S2320

Clinical - Urology

ESTRO 2024

patients (8.2%). Overall, after a median follow up of 17 months, Median BRFS was 25 months (95% CI 20-63), while MFS and ADT free survival were not reached.

No:

130

(74.7)

Previous postoperative RT (%)

Yes:44 (25.3)

Age (median value, IQR)

69 years (63-74)

PSA at recurrence (median value, IQR)

0.41 ng/ml (0.28-0.56)

T2

a-c:

47

(27)

Baseline T stage (%)

T3a:

93

(53.5)

T3b: 34 (19.5)

N0:

108

(62)

Baseline N stage (%)

N+:

13

(7.5)

Nx 53 (30.5)

R0:109

(62.6)

Margin status (%)

R1: 65 (37.4)

1:9

(5.2)

2:49

(28.2)

Baseline ISUP pattern (%)

3:58

(33.3)

4:35

(20.1)

5:23 (13.2)

Conclusion:

In this cohort including patients affected by early biochemical relapse, PSMA imaging led to detection of pelvic or metastatic disease in a significative proportion of patients, leading to a change in standard management if compared to standard SRT. The results of PSMA PET/Ct imaging provide an important and reliable means to tailor treatment in a significant percentage of enrolled cases. These patients would probabily not have received optimal management in a pre-PSMA scenario. A PSMA targeted treatment strategy led to promising results within a prospective multicentric trial. Majority of patients remained free from ADT after this approach, avoiding unnecessary treatment toxicity.

Keywords: Prostate cancer, recurrence, PSMA PET/CT;

References:

1) Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS Jr, Faraday MM (2013 Aug) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 190(2):441 – 449 2) Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG (2020) ; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET- CT in patients with high-risk prostate cancer before curative-intent